ACS Nano · 2018 · 116 citations · 30 references
MedicineOncologyUrologyBiomedical ImagingMolecular ImagingNanomaterialsBiomarkers In Urologic OncologyCancer NanomedicineNanocarriers For TherapeuticsNanomedicineNanoparticle CharacterizationRaman SpectroscopyMultiplexed ImagingNanoparticlesPassive Tumor TargetingRaman ImagingSurface-enhanced Raman ScatteringSurface-enhanced Raman SpectroscopyTissue ClassificationTissue Permeability
Bladder cancer has the highest recurrence rate of all cancers due in part to inadequate transurethral resection. Inadequate resection is caused by the inability of cystoscopes to detect invisible lesions during the resection procedure. To improve detection and resection of nonmuscle invasive bladder cancer, we quantified the ability of a surface-enhanced Raman nanoparticle and endoscope system to classify bladder tissue as normal or cancerous. Both antibody-based (active) and tissue permeability-based (passive) targeting mechanisms were evaluated by topically applying nanoparticles to ex vivo human bladder tissue samples. Multiplexed molecular imaging of CD47 and Carbonic Anhydrase 9 tumor proteins gave a receiver operating characteristic area under the curve (ROC AUC of 0.93 (0.75, 1.00). Furthermore, passively targeted nanoparticles enabled tissue classification with an ROC AUC of 0.93 (0.73, 1.00). Passively targeted nanoparticles penetrated 5-fold deeper and bound to tumor tissue at 3.3-fold higher concentrations in cancer compared to normal bladder urothelium, suggesting the existence of an enhanced surface permeability and retention effect in human bladder cancer.
30
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Xavier Robin, Natacha Turck, Alexandre Hainard et al. · BMC Bioinformatics · 2011 · 14K citations · Full text
Cristina Zavaleta, Bryan Ronain Smith, Ian D. Walton et al. · Proceedings of the National Academy of Sciences · 2009 · 716 citations · Full text
Natural Sciences, Bioengineering, Biomedical Engineering +16
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu, Lijuan Wang, Feifei Zhao et al. · PLoS ONE · 2015 · 472 citations · Full text
Pharmacy, Immunology, Oncology +17